Journal of Clinical Oncology
Articles in this Issue
Four-year landmark survival analysis of low-dose nivolumab added to metronomic chemotherapy in advanced head and neck squamous cell carcinoma: A phase III randomized trial.
6054 Background: In advanced head and neck squamous cell carcinoma (HNSCC), the addition of low-dose nivolumab to triple m...
Efficacy and safety of perioperative anlotinib combined with cisplatin and doxorubicin in treatment-naive stage IIB classic osteosarcoma of the extremity: Updated results from the ALTER-S002 trial.
11526 Background: Clinical studies show overexpression of multiple tyrosine kinase receptors in osteosarcoma, supporting t...
Real-world treatment patterns and clinical outcomes among US patients with non-muscle invasive bladder cancer (NMIBC) during the BCG shortage.
4612 Background: Bladder cancer is diagnosed in 80,000 US patients (pts) annually; 70% present as non-muscle invasive (NMI...
Effects of RNA-based NGS on false-positive fusion calls in colorectal cancer compared with DNA-NGS.
e15575 Background: Gene fusions act as oncogenic drivers across multiple solid tumors and provide opportunities for matche...
Durable efficacy of first-line necitumumab plus pembrolizumab in PD-L1–high advanced NSCLC: Final results of the phase II K-TAIL-202 study.
8573 Background: Pembrolizumab is a standard 1st line treatment for advanced non–small cell lung cancer (NSCLC) with high...
Light-activated EGFR antibody–drug conjugate: Analysis of selectivity and translational profile for first-in-human evaluation.
3023 Background: Conventional antibody–drug conjugates (ADCs) are limited by systemic toxicity and narrow therapeutic wind...
H&E–based MSI/MMR testing with artificial intelligence in colorectal cancer: A blinded evaluation across diverse clinicopathological subgroups.
3520 Background: Mismatch repair (MMR) deficiency and microsatellite instability (MSI) testing is integral to colorectal c...
Clinical characteristics and survival outcomes of a large cohort of patients diagnosed with diffuse large B-cell lymphoma: Data from the GOTEL Lymphoma Registry.
e19070 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. It is a heter...
Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and response to front-line systemic therapy.
e16556 Background: Genomic alterations in RCC can serve as biomarkers for response to therapy. Wild type VHL has shown inf...
Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.
4613 Background: Results from the phase 3 KEYNOTE-905/EV-303 study (NCT03924895) showed that neoadj-adj EV + pembro and ra...
Clinical outcomes of solid basaloid and classic adenoid cystic carcinoma of the breast.
e12746 Background: Adenoid cystic carcinoma (AdCC) of the breast is a rare ( < 0.1%) form of breast cancer with two var...
Translating real-world data into actionable insights: An AI-powered model for prostate cancer survival prediction in a Brazilian cohort.
e23449 Background: Prostate cancer (PCa) outcomes are shaped by a complex interplay of clinical and socioeconomic factors....
Association of early on-treatment cytokine dynamics following induction chemo-immunotherapy with progression-free survival in squamous non–small cell lung cancer.
e20560 Background: Despite advances in immunotherapy-based combinations for advanced non–small cell lung cancer (NSCLC), b...
Efficacy outcomes in first-line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT-2.023 randomized phase 3 study of IL-15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy.
8588 Background: Baseline and treatment-induced lymphopenia are adverse prognostic factors in NSCLC and may limit CPI dura...
Firmonertinib combined with platinum-based chemotherapy in patients with <i>EGFR</i> -mutant advanced NSCLC following disease progression on first-line third-generation EGFR-TKI.
8610 Background: Patients (pts) who have progressed after first-line 3rd-generation EGFR-TKIs treatment exhibit limited th...
Pathologic complete response with neoadjuvant chemoimmunotherapy in clinical stage II–III NSCLC: A large real-world analysis including older adults.
8055 Background: Neoadjuvant chemoimmunotherapy is now the standard for clinical stage II-III non-small cell lung cancer (...
SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study.
8527 Background: SHR-A2102 is a novel antibody-drug conjugate composed of a monoclonal antibody targeting nectin-4, a clea...
Association of pre-diagnosis primary care utilization with metastatic disease, treatment adherence, and mortality in colorectal cancer.
3664 Background: In addition to timely evaluation and screening in patients with colorectal cancer (CRC), routine primary...
First-in-human phase I study of CEB-01, a biodegradable SN-38–releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results.
e23559 Background: Local recurrence is the main cause of mortality in retroperitoneal sarcoma (RPS), and perioperative sys...
Evaluation of a remote electronic assessment of survivors with tailored follow-up recommendations and survivorship messaging (REASSURE) to improve the delivery of follow-up for low-risk breast cancer survivors.
1669 Background: Current follow-up care for the 2 million+ low-risk breast cancer survivors fails to adequately address su...
Breast cancer screening is heating up: A novel thermophysics-based AI modality for screening subjects with BIRADS 4 or 5 mammograms.
3064 Background: Although mammography is an effective cancer detection modality, limited specificity at population scale l...
Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.
7567 Background: Older patients with newly diagnosed multiple myeloma (MM) frequently experience early treatment discontin...
Opportunities for breast cancer prevention among pediatric lymphoma survivors treated with chest radiation: Projected gap in breast cancer deaths with real-world uptake rates.
10048 Background: For survivors of pediatric lymphoma previously treated with chest radiotherapy (RT), the Children’s Onco...
AACR GENIE analysis of 211,526 patients to evaluate hormone receptor alterations across solid tumors: Rationale for tissue-agnostic basket trials.
3133 Background: Steroid Hormone receptors (HR) that include estrogen receptor (ER), progesterone receptor (PR), and andro...
Adjuvant immunotherapy following upfront surgery for stage II–III triple-negative breast cancer: A National Cancer Database Study.
e12520 Background: In early-stage triple-negative breast cancer (TNBC), immunotherapy (IO) improves outcomes when administ...